The role of miRNA -150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients
Keywords:KEYWORDS: CML, Imatinib mesylate, miRNA, miRNA-150
The dysregulation of miRNA expression patterns is one of the many effects developments of cancer, miRNA has been found to express abnormally in hematological neoplasia such as chronic myeloid leukemia and solid malignancies. Resistance and the degree of response following tyrosine kinase inhibitor treatment are correlated with miRNA expression. Hence, in this study we tried to study the relationship of miRNA-150 between different breakpoint cluster region–Abelson (BCR- ABL) P210 transcript levels and the role miRNA- 150 between different levels of imatinib optimal response in chronic myeloid leukemia (CML). Our study included sixty chronic myeloid leukemia (CML) patients they were divided into two groups based on response to imatinib therapy, thirty samples of the optimal molecular response of chronic myeloid leukemia (CML) patients, and thirty samples of failure molecular response chronic myeloid leukemia (CML) patients. Thirty samples of apparently healthy volunteers were included and evaluated as control. According to the P210 BCR-ABL%, the results showed a significant difference (P= < 0.0001) between the responder and the failure response CML patients. Assessed the result of miRNA-150 showed a significant difference between both CML patients (P = < 0.0001), assessed miRNA-150 level among different response groups, and failure response of CML patients (P = 0.0002). A cutoff value of response vs. failure response (1.784) with high sensitivity can be a diagnostic value to differentiate between response and failure response. Changing gene expression with different amounts of miRNAs had an impact on drug-gene interactions, with consequences for cell growth and death. Gene expression of different levels miRNA-150 among of CML patients of imatinib therapy showed high expression in response patients than failure response patients. The gene expression level of miRNA-150 differs through different responses in CML patients.
B. E. Aïnseba and C. Benosman, "Global dynamics of hematopoietic stem cells and differentiated cells in a chronic myeloid leukemia model," Journal of mathematical biolog, vol. 62, no. 6, pp. 975-997, 2011.
L.-h. Xu, Y. Guo, X.-L. Zhang, J.-j. Chen, and S.-y. Hu, "Blood-based circulating microRNAs are potential diagnostic biomarkers for leukemia: result from a meta-analysis," Cellular Physiology Biochemistry, vol. 38, no. 3, pp. 939-949, 2016.
R. H. Abdulridha, N. K. Jawad, A. T. Numan, and Toxicology, "Prevalence and Risk of Leukemia Reported Cases, Observational Descriptive Statistic from Iraqi Center for Hematology in Baghdad Province," Indian Journal of Forensic Medicine, vol. 15, no. 1, p. 2429, 2021.
R. Alves et al., "Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance," Cancers, vol. 13, no. 19, p. 4820, 2021.
M. W. Deininger et al., "Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology," Journal of the National Comprehensive Cancer Network, vol. 18, no. 10, pp. 1385-1415, 2020.
M. M. Sampaio et al., "Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review," World Journal of Clinical Oncology, vol. 12, no. 2, p. 69, 2021.
B. F. Matti, A. F. Alwan, and A. F. Alwan, "Evaluation of the safety of imatinib mesylate in 200 Iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study," Turkish Journal of Hematology, vol. 30, no. 4, p. 387, 2013.
S. F. S. Mohamad and M. H. Elias, "Potential treatment for chronic myeloid leukemia using microRNA: in silico comparison between plants and human microRNAs in targeting BCR-ABL1 gene," Egyptian Journal of Medical Human Genetics, vol. 22, no. 1, pp. 1-8, 2021.
N. Khoshnaw, B. Francis, B. M. Safar, S. S. Mahmood, and B. F. Nore, "Cytogenetic response in chronic myeloid leukaemia patients treated with imatinib mesylate homolog-drugs: 6 year's transitional study," Journal of Cancer Therapy, vol. 2014, 2014.
E. Jabbour, A. Hochhaus, J. Cortes, P. La Rosée, and H. Kantarjian, "Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history," Leukemia, vol. 24, no. 1, pp. 6-12, 2010.
C. Di Stefano, G. Mirone, S. Perna, and G. Marfe, "The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia," Oncology reports, vol. 35, no. 2, pp. 614-624, 2016.
N. Abd-Aziz, N. I. Kamaruzman, and C. L. Poh, "Development of MicroRNAs as Potential Therapeutics against Cancer," Journal of Oncology, vol. 2020, p. 8029721, 2020/07/15 2020. https://doi.org/10.1155/2020/8029721
N. Hosseinahli, M. Aghapour, P. H. Duijf, and B. Baradaran, "Treating cancer with microRNA replacement therapy: A literature review," Journal of cellular physiology, vol. 233, no. 8, pp. 5574-5588, 2018.
L. Anelli, A. Zagaria, G. Specchia, P. Musto, and F. Albano, "Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers," International Journal of Molecular Sciences, vol. 22, no. 13, p. 7156, 2021.
D. P. Bartel, "Metazoan micrornas," Cell, vol. 173, no. 1, pp. 20-51, 2018.
A. Szymczyk, A. Macheta, and M. Podhorecka, "Abnormal microRNA expression in the course of hematological malignancies," Cancer management research, vol. 10, p. 4267, 2018.
D. T. Starczynowski et al., "Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations," Blood, The Journal of the American Society of Hematology, vol. 117, no. 2, pp. 595-607, 2016.
A. Hochhaus et al., "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia," Leukemia, vol. 34, no. 4, pp. 966-984, 2020.
D. Hu et al., "Intricate crosstalk between MYB and noncoding RNAs in cancer," Cancer Cell International, vol. 21, no. 1, pp. 1-15, 2021.
K. M. Poláková et al., "Expression patterns of microRNAs associated with CML phases and their disease related targets," Molecular cancer, vol. 10, no. 1, pp. 1-13, 2011.
O. B. Ezeanosike and O. Afonne, "Prognostic significance of micro RNA 150 marker in BCR-ABL positive chronic myeloid leukaemia patients on imatinib mesylate," International Journal of Contemporary Pediatrics, vol. 4, no. 5, p. 1557, 2017.
A. J. E. R. O. H. Zámečníkova, "Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer," vol. 3, no. 1, pp. 45-56, 2010.
How to Cite
Copyright (c) 2023 Al-Mustansiriyah Journal of Science
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Articles accepted for publication in Al-Mustansiriyah Journal of Science (MJS) are protected under the Creative Commons Attribution 4.0 International License (CC BY-NC). Authors of accepted articles are requested to sign a copyright release form prior to their article being published. All authors must agree to the submission, sign copyright release forms, and agree to be included in any correspondence between MJS and the authors before submitting a work to MJS. For personal or educational use, permission is given without charge to print or create digital copies of all or portions of a MJS article. However, copies must not be produced or distributed for monetary gain. It is necessary to respect the copyright of any parts of this work that are not owned by MJS.